VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZBH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZBHZimmer Biomet Holdings, Inc.
$103.32$20.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksZBHFinancials

Zimmer Biomet Holdings, Inc. (ZBH) Income Statement

27Y historyFree accessUpdated daily

Revenue growth has oscillated between 1.1% and 11.4% year over year and decelerated to 3.1% in Q3 2026, while gross margin ranged from 64.7% to 72.4% and operating margin from 12.8% to 19.2%, with EPS swinging between $0.70 and $1.23 more sharply than revenue, which may indicate significant non-operating or tax-related influences.

Income StatementBalance SheetCash FlowRatios

ZBH Income Statement

Annual statement

ZBH Income Statement

Zimmer Biomet Holdings, Inc. (ZBH) annual income statement — 27-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Sales/Revenue8.57B8.23B7.68B7.39B6.94B6.83B6.13B7.98B7.93B7.8B7.67B6B4.67B4.62B4.47B4.45B4.22B4.1B4.12B3.9B3.5B3.29B2.98B1.9B1.37B1.18B1.04B939M
Revenue Growth %6.98%7.2%3.85%6.55%1.65%11.42%-23.24%0.62%1.66%1.76%27.85%28.34%1.08%3.39%0.45%5.49%3.05%-0.62%5.74%11.5%6.37%10.24%56.81%38.52%16.44%13.26%10.82%-
Cost of Goods Sold2.6B3.16B2.19B2.08B2.02B1.96B1.82B2.25B2.27B2.13B2.38B1.8B1.24B1.29B1.13B1.12B1.01B990.7M997.3M875.9M780.1M739.4M779.9M516.2M344.8M325.9M290.9M269M
COGS % of Revenue-38.38%28.54%28.18%29.1%28.71%29.77%28.22%28.64%27.33%31.06%30.02%26.59%27.82%25.16%25.2%23.98%24.19%24.2%22.47%22.32%22.5%26.16%27.15%25.12%27.65%27.96%28.65%
Gross Profit5.97B5.07B5.49B5.31B4.92B4.87B4.3B5.73B5.66B5.67B5.29B4.2B3.43B3.34B3.35B3.33B3.21B3.1B3.12B3.02B2.72B2.55B2.2B1.38B1.03B852.7M749.7M670M
Gross Margin %69.68%61.62%71.46%71.82%70.9%71.29%70.23%71.78%71.36%72.67%68.94%69.98%73.41%72.18%74.84%74.8%76.02%75.81%75.8%77.53%77.68%77.5%73.84%72.85%74.88%72.35%72.05%71.35%
Gross Profit Growth %--7.57%3.33%7.93%1.1%13.1%-24.9%1.21%-0.17%7.26%25.96%22.35%2.79%-0.27%0.5%3.8%3.33%-0.61%3.38%11.28%6.62%15.71%58.94%34.76%20.51%13.74%11.9%-
Operating Expenses4.68B3.71B4.2B4.03B4.22B4.01B4.22B4.59B5.63B4.87B4.47B3.73B2.39B2.04B2.3B2.31B2.29B2.09B2.03B1.89B1.55B1.49B1.44B934.1M626.7M604.4M481.7M439M
OpEx % of Revenue-45.07%54.72%54.54%60.87%58.68%68.87%57.53%70.94%62.42%58.23%62.19%51.21%44.08%51.41%51.79%54.29%50.93%49.35%48.6%44.35%45.39%48.23%49.14%45.66%51.28%46.29%46.75%
Selling, General & Admin3.47B3.25B2.93B2.84B2.76B2.84B2.71B3.34B3.38B3.1B2.94B2.66B1.98B1.83B1.91B1.86B1.77B1.76B1.77B1.49B1.36B1.26B1.19B737.5M546M532.8M429.7M394M
SG&A % of Revenue-39.5%38.16%38.39%39.79%41.65%44.27%41.89%42.6%39.79%38.4%44.36%42.33%39.66%42.76%41.86%41.85%43.07%43.02%38.22%38.79%38.33%39.92%38.8%39.78%45.21%41.29%41.96%
Research & Development432.9M458.5M437.4M458.7M406M435.8M322.8M449.3M391.7M369.9M365.6M268.8M191.9M204.2M225.6M238.4M218.5M205.7M192.3M209.6M188.3M175.5M166.7M105.8M80.7M71.6M52M45M
R&D % of Revenue-5.57%5.7%6.2%5.85%6.38%5.27%5.63%4.94%4.74%4.77%4.48%4.11%4.42%5.05%5.36%5.18%5.02%4.67%5.38%5.39%5.34%5.59%5.57%5.88%6.08%5%4.79%
Other Operating Expenses4M0834.5M735.1M1.06B727.4M1.18B799M1.86B1.4B1.16B800.6M223.1M6M161.2M203.8M306.8M116.2M68.5M194.7M6.1M56.6M81.1M90.8M0000
Operating Income1.29B1.36B1.29B1.28B696.3M860.3M83.1M1.14B33.8M799.3M821.1M467.3M1.04B1.04B1.05B1.02B916.7M1.02B1.09B1.13B1.17B1.05B763.2M450.7M400.9M248.3M268M231M
Operating Margin %15.11%16.55%16.74%17.28%10.03%12.6%1.36%14.25%0.43%10.24%10.71%7.79%22.2%22.4%23.42%23%21.72%24.88%26.45%28.93%33.34%32.1%25.6%23.71%29.21%21.07%25.75%24.6%
Operating Income Growth %-5.95%0.63%83.5%-19.06%935.26%-92.69%3265.38%-95.77%-2.66%75.71%-54.95%0.16%-1.13%2.28%11.72%-10.02%-6.53%-3.33%-3.23%10.45%38.23%69.34%12.42%61.46%-7.35%16.02%-
EBITDA2.4B2.46B2.28B2.23B1.62B1.8B981.5M2.14B1.07B1.86B1.86B1.18B1.41B1.39B1.41B1.38B1.26B1.36B1.37B1.36B1.36B1.24B944.5M554M426.2M271.7M291.1M253M
EBITDA Margin %28.02%29.84%29.72%30.15%23.38%26.34%16.02%26.85%13.54%23.86%24.26%19.67%30.24%30.15%31.54%31.09%29.78%33.12%33.12%34.83%38.98%37.76%31.69%29.14%31.06%23.05%27.97%26.94%
EBITDA Growth %-0.19%7.62%2.36%37.39%-9.75%83.19%-54.21%99.53%-42.3%0.09%57.7%-16.52%1.36%-1.16%1.91%10.11%-7.32%-0.65%0.55%-0.37%9.83%31.36%70.49%29.99%56.86%-6.66%15.06%-
D&A (Non-Cash Add-back)1.11B1.09B996.3M951.7M926.4M937.7M898.4M1.01B1.04B1.06B1.04B712.4M375.8M358.5M363.1M359.9M340.2M337.4M275.1M230M197.4M185.7M181.3M103.3M25.3M23.4M23.1M22M
EBIT1.18B1.12B1.25B1.27B568.3M707.4M106.9M1.13B18.2M789.9M754.6M439.8M1B1.05B1.06B1.03B920.4M1.14B1.16B1.15B1.17B1.11B844.3M541.5M400.9M248.3M268M231M
Net Interest Income-288.5M-292.8M-218M-201.2M-164.8M-208.4M-212.1M-226.9M-289.3M-325.3M-355M-277.2M-51.2M-54.5M-57.3M-45.2M-56.5M-20.6M31.8M000000000
Interest Income000000000009.4M11.9M15.6M15.6M10.1M3.7M031.8M000000000
Interest Expense288.5M292.8M218M201.2M164.8M208.4M212.1M226.9M289.3M325.3M355M286.6M63.1M70.1M72.9M55.3M60.2M20.6M0000000000
Other Income/Expense-410.2M-531.4M-249.1M-210.4M-292.8M-361.3M-188.3M-231.7M-304.9M-334.7M-421.5M-314.1M-97.9M-87.5M-57.3M-45.2M-56.5M-20.6M31.8M4M3.8M-14.3M-31.7M-13.2M-12M-7.4M00
Pretax Income884.5M830.8M1.04B1.07B403.5M499M-105.2M905.8M-271.1M464.6M399.6M153.2M939.4M981.1M990.1M978.9M860.2M998.2M1.12B1.13B1.17B1.04B731.5M437.5M388.9M240.9M268M231M
Pretax Margin %10.32%10.09%13.5%14.43%5.81%7.31%-1.72%11.35%-3.42%5.95%5.21%2.55%20.1%21.22%22.14%21.99%20.38%24.37%27.22%29.03%33.44%31.67%24.54%23.01%28.34%20.44%25.75%24.6%
Income Tax115.8M125.7M131.4M42.2M112.3M53.5M-96M-225.7M108.2M-1.35B95M7M220.2M221.9M237.2M218.9M263.3M280.8M272.3M357.9M334M307.3M189.6M146.8M131.1M91.1M92M81M
Effective Tax Rate %13.09%15.13%12.68%3.95%27.83%10.72%91.25%-24.92%-39.91%-290.31%23.77%4.57%23.44%22.62%23.96%22.36%30.61%28.13%24.27%31.63%28.57%29.53%25.92%33.55%33.71%37.82%34.33%35.06%
Net Income767.5M705.2M903.8M1.02B231.4M401.6M-138.9M1.13B-379.2M1.81B305.9M147M720.3M761M755M760.8M596.9M717.4M848.6M773.2M834.5M732.5M541.8M346.3M257.8M149.8M176M150M
Net Margin %8.96%8.57%11.77%13.85%3.33%5.88%-2.27%14.18%-4.78%23.24%3.99%2.45%15.41%16.46%16.88%17.09%14.14%17.52%20.59%19.84%23.87%22.29%18.18%18.22%18.78%12.71%16.91%15.97%
Net Income Growth %-4.68%-21.97%-11.74%342.52%-42.38%389.13%-112.27%398.42%-120.91%492.94%108.1%-79.59%-5.35%0.79%-0.76%27.46%-16.8%-15.46%9.75%-7.35%13.92%35.2%56.45%34.33%72.1%-14.89%17.33%-
Net Income (Continuing)768.7M705.1M905.2M1.03B291.2M445.5M-9.2M1.13B-379.3M1.81B304.6M146.2M719M759.2M752.9M760M596.9M717.4M849.5M773.2M834.5M732.5M541.8M291.2M257.8M149.8M176M150M
Discontinued Operations0000-58.8M-43.4M-128.2M000000000000000000000
Minority Interest10M8.1M8.1M7.7M6.7M5.7M5.2M4.7M4.8M-300K1M1.5M1.8M2.8M5.4M7.6M003.6M2.8M2.7M2.3M7.1M7M0000
EPS (Diluted)4.013.554.434.881.101.85-0.655.31-1.818.771.460.264.194.434.294.032.973.323.723.263.402.932.191.641.310.770.910.77
EPS Growth %-2.23%-19.86%-9.22%343.64%-40.68%385.07%-112.25%394.09%-120.6%502%460.12%-93.79%-5.42%3.26%6.45%35.69%-10.54%-10.75%14.11%-4.12%16.04%33.79%33.54%25.19%70.13%-15.38%18.18%-
EPS (Basic)-3.564.454.911.101.87-0.655.36-1.818.841.470.274.264.494.324.062.983.343.733.283.432.962.221.671.330.770.910.77
Diluted Shares Outstanding191.4M198.7M203.9M209.7M210.3M216.71M213.21M212.9M209.6M209.81M208.47M189.8M171.7M171.8M176M188.7M201.1M215.8M228.3M237.5M245.4M249.8M247.8M211.2M196.8M194.3M193.6M193.6M
Basic Shares Outstanding190.5M198M203.1M208.7M209.6M214.86M213.21M211.25M209.6M207.96M206M187.4M169M169.6M174.9M187.6M200M215M227.3M235.5M243M247.1M244.4M207.7M194.5M193.7M193.6M193.6M
Dividend Payout Ratio-26.99%21.69%19.62%86.95%49.83%-17.38%-10.67%61.59%106.87%20.2%17.4%12.5%67.09%---------193.59%--

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

China VBP price erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Low-Single-Digit Growth Persists Despite Volatility

Based on reported quarterly figures, ZBH's revenue growth has oscillated between 1.1% and 11.4% year over year over the last ten quarters, with the most recent print at 3.1% suggesting a deceleration from the 9.3% reported in the prior cycle.

The quarterly series shows growth clustering in a low-to-mid single-digit band rather than accelerating, which may indicate that volume gains are being offset by price concessions in mature implant lines. The swings appear partly tied to timing effects and the ZimVie separation, so year-over-year comparisons should be treated with caution. Investors should monitor whether the cementless knee mix and ROSA adoption can lift growth durably above this band.

Gross Margin Oscillates Around Seventy Percent

As reported in quarterly financial statements, ZBH's gross margin ranged from 64.7% to 72.4% over the period, with the latest quarter at 71.2%, indicating a structurally high but cyclically variable margin profile.

The gross margin band appears to be relatively stable in the low-70s outside of isolated dips, which is consistent with a franchise supported by specialized implant pricing. The troughs, particularly the 64.7% print, may reflect inventory charges or mix effects rather than a permanent shift, though the data alone cannot confirm the cause. Continued pressure from GPO price concessions and APAC deflation would likely be the primary threat to sustaining these levels.

Operating Margin Shows Limited Scaling

Based on reported figures, ZBH's operating margin has fluctuated between 12.8% and 19.2%, and the latest 14.9% reading suggests operating income is not consistently scaling with gross profit across quarters.

SG&A remains the dominant expense line, running at roughly 40% of revenue, so modest revenue growth translates into limited operating leverage. The inconsistency between gross profit stability and operating margin volatility suggests overhead and commercial spend absorb much of any incremental gross profit. This pattern warrants further investigation into whether the expense base can be structurally reduced.

EPS Volatility Outpaces Revenue Trend

According to reported quarterly data, ZBH's diluted EPS swung between $0.70 and $1.23 over ten quarters, a range far wider than the revenue trend, which may indicate significant non-operating or tax-related influences on reported earnings.

Net margin variability from 6.2% to 13.7% is considerably larger than gross margin variability, implying that below-the-line items such as tax rate changes, interest, or one-time charges materially affect reported profit. Stock-based compensation of roughly $20-26 million per quarter is modest relative to net income and does not appear to explain the swings. The most recent EPS miss relative to consensus, noted in company commentary, further suggests earnings conversion is an area requiring monitoring.

Margin Erosion Risk from Price Deflation

The strongest bear case is that ZBH's Q4 2025 gross margin trough at 64.7% and recurring APAC pricing pressure from China's VBP program may signal structural erosion rather than one-time noise, though this remains an inference from limited quarterly data.

If GPO price concessions and VBP-driven deflation continue to compound, the current low-70s gross margin could drift lower, compressing operating income even if unit volumes grow. Revenue growth that has decelerated to 3.1% in the latest quarter, combined with an EPS decline of 13.8% year over year, would be consistent with this downside scenario. Investors should monitor gross margin trajectory closely, as the thesis depends on mix shift offsetting price erosion.

ZBH — Frequently Asked Questions

Quick answers to the most common questions about buying ZBH stock.

What was Zimmer Biomet Holdings, Inc.'s (ZBH) revenue in 2025?

For fiscal year 2025, Zimmer Biomet Holdings, Inc. (ZBH) reported total revenue of $8.23B. This represents a 776.6% increase compared to $939.0M in 1999.

Is Zimmer Biomet Holdings, Inc. (ZBH) profitable?

Zimmer Biomet Holdings, Inc. (ZBH) is profitable, generating $705.2M in net income for the fiscal year ending 2025 with a net profit margin of 8.6%.

What is Zimmer Biomet Holdings, Inc.'s operating profit margin?

Zimmer Biomet Holdings, Inc. (ZBH) reported an operating income of $1.36B, resulting in an operating profit margin of 16.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Zimmer Biomet Holdings, Inc.'s gross profit and gross margin?

Zimmer Biomet Holdings, Inc. (ZBH) generated $5.07B in gross profit for the year, representing a gross profit margin of 61.6%. This demonstrates the company's core pricing power and production efficiency.